Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022

Rhea-AI Summary

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced a scheduled business update and preliminary financial results for Q4 and fiscal year 2021 on March 21, 2022. The conference call will take place at 8:00 a.m. ET, where the company will discuss its innovative therapeutics aimed at treating seizure disorders, including their lead drug, Ganaxolone. Ganaxolone is designed to enhance GABA_A receptor activity, offering potential benefits for both adult and pediatric patients.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ended December 31, 2021 before the market opens on March 21, 2022. The company will host a conference call at 8:00 a.m. Eastern Time on March 21, 2022, to provide a business update and discuss the financial results.

Monday, March 21, 8:00 a.m. ET

Domestic: +1 (888) 550-5280
International: (646) 960-0813
Webcast Link: https://events.q4inc.com/attendee/991025183
Conference ID: 2696394

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220216005461/en/

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

484-253-6792

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

What date will Marinus Pharmaceuticals report its Q4 2021 results?

Marinus Pharmaceuticals will report its Q4 2021 results on March 21, 2022.

What is the focus of Marinus Pharmaceuticals' upcoming conference call?

The upcoming conference call will focus on a business update and preliminary financial results for Q4 and fiscal year 2021.

What time is Marinus Pharmaceuticals' conference call scheduled for?

The conference call is scheduled for 8:00 a.m. Eastern Time on March 21, 2022.

What is Ganaxolone and its significance to Marinus Pharmaceuticals?

Ganaxolone is Marinus Pharmaceuticals' lead drug, acting as a positive allosteric modulator of GABA_A receptors, aimed at treating seizure disorders.

How can I access the conference call for Marinus Pharmaceuticals?

You can access the conference call by calling +1 (888) 550-5280 domestically or (646) 960-0813 internationally.